<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04244084</url>
  </required_header>
  <id_info>
    <org_study_id>MMH-407-001</org_study_id>
    <nct_id>NCT04244084</nct_id>
  </id_info>
  <brief_title>Clinical Trial of Efficacy and Safety of ММН-407 in Acute Respiratory Viral Infection</brief_title>
  <official_title>Multicenter Double-blind Placebo-controlled Parallel Group Randomized Clinical Trial of Efficacy and Safety of MMH-407 in the Treatment of Acute Respiratory Viral Infection</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Materia Medica Holding</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Materia Medica Holding</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To evaluate the efficacy and safety of ММН-407 in treatment of acute respiratory viral&#xD;
      infection (ARVI).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Design: multicenter, double blind, placebo-controlled, parallel group randomized clinical&#xD;
      trial.&#xD;
&#xD;
      The study will enroll outpatients of either gender aged 18-70 years old with clinical&#xD;
      manifestations of ARVI within the first day after the onset of the disease during seasonal&#xD;
      ARVI morbidity.&#xD;
&#xD;
      After signing patient information sheet and informed consent form, medical history,&#xD;
      thermometry, objective examination, laboratory tests and concomitant medication will be&#xD;
      performed. Severity of ARVI symptoms is evaluated with 4-point scale.&#xD;
&#xD;
      The nasopharyngeal swabs for PCR diagnosis and verification of respiratory viruses will be&#xD;
      performed prior to therapy to confirm the viral etiology of ARVI.&#xD;
&#xD;
      If a patient meets all inclusion criteria and does not have any exclusion criteria, at Visit&#xD;
      1 (Day 1) he/she will be randomized into one of two groups: the 1st group will take MMH-407&#xD;
      according to the dosage regimen for 5 days; the 2nd group will take Placebo according to&#xD;
      MMH-407 dosage regimen for 5 days.&#xD;
&#xD;
      The study will use electronic patient diary for recording morning and evening axillary body&#xD;
      temperature (measured using a mercury-free Geratherm Classic thermometer) and disease&#xD;
      symptoms (Symptom Severity Score). Besides, antipyretic dosing (if applicable) and any&#xD;
      aggravation in a patient's condition (if applicable, for safety evaluation/AE documentation)&#xD;
      will also be recorded in a patient diary. The investigator will provide instructions on&#xD;
      filling the diary; at Visit 1 the patient together with a doctor will record ARVI symptom&#xD;
      severity and body temperature in the diary.&#xD;
&#xD;
      Patient will be observed for 14 days (screening, randomization - Day 1, treatment period - 5&#xD;
      days, follow-up - up to 2 days; deferred &quot;phone visit&quot; - Day 14).&#xD;
&#xD;
      During the treatment and follow-up period the patients or investigators will make 3 visits&#xD;
      and the fourth &quot;phone visit&quot; will be scheduled additionally: 1) visits by physician/patient -&#xD;
      on Days 1, 5 and 7 (Visits 1, 2 and 3) - in a study center or at home; 2) &quot;phone visit&quot;&#xD;
      (Visit 4) - on Day 14.&#xD;
&#xD;
      At Visits 2 and 3, the investigator will perform an objective examination, document changes&#xD;
      in the symptoms and concomitant medications to check patient diaries. At Visit 3 compliance&#xD;
      will be evaluated and laboratory tests will be performed. &quot;Phone visit&quot; is carried out to&#xD;
      interview the patient about his/her condition, presence/absence of secondary bacterial/viral&#xD;
      complications and use of antibiotics.&#xD;
&#xD;
      During the study, symptomatic therapy and therapy for their co-morbidities are allowed with&#xD;
      the exception of the drugs indicated in the section &quot;Prohibited Concomitant Treatment&quot;.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">October 8, 2019</start_date>
  <completion_date type="Actual">April 9, 2020</completion_date>
  <primary_completion_date type="Actual">April 9, 2020</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Time to Resolution of Acute Respiratory Viral Infection (ARVI) Symptoms</measure>
    <time_frame>14 days of observation.</time_frame>
    <description>Outcome Measure is evaluated on the basis of the &quot;ARVI severity scale&quot; to calculate total symptom score (TSS) in patients with confirmed virus by Polymerase chain reaction (PCR).&#xD;
ARVI's resolution criteria: temperature ≤37.3°С + TSS ≤2. Axillar temperature, 6 flu-like nonspecific symptoms (headache, chills, sweating, weakness, muscle pain, drowsiness), and 6 nasal/throat/chest symptoms (runny nose, nasal congestion, sneezing, hoarseness, sore throat, cough) were registered for TSS according to the 4-point scale for each of them (0 = no symptom; 1 = mild symptom; 2 = moderate symptom; 3 = severe symptom). To calculate TSS absolute axillar temperature (in degrees Celsius) was converted to relative units (or points) using the following scale: ≤37.3 С=0 points; 37.4-38.0 С=1 point; 38.1-39.0 С=2 points; ≥39.1 С=3 points. The range of TSS was from &quot;0&quot; to &quot;39&quot;.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Severity of ARVI (Clinically Diagnosed and/or PCR-confirmed)</measure>
    <time_frame>On days 1- 6 of the observation.</time_frame>
    <description>Outcome Measure is based on the area under the curve (AUC) for TSS. AUC was calculated between 6 points (by TSS for every 6 days of the treatment and observation). The minimum value for the AUC was &quot;0&quot; and the maximum value was &quot;234&quot; units (day*score). Higher TSS and AUC scores meant worse results.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Patients With Resolution of ARVI Symptoms (Clinically Diagnosed and/or PCR-confirmed)</measure>
    <time_frame>On days 3, 4, 5 and 6 of observation.</time_frame>
    <description>ARVI's resolution criteria: temperature ≤37.3°С + total symptom score (TSS) ≤2. Axillar temperature, 6 flu-like nonspecific symptoms (headache, chills, sweating, weakness, muscle pain, drowsiness) and 6 nasal/throat/chest symptoms (runny nose, nasal congestion, sneezing, hoarseness, sore throat, cough) were registered for TSS according to the 4-point scale for each of them (0 = no symptom; 1 = mild symptom; 2 = moderate symptom; 3 = severe symptom). To calculate TSS absolute axillar temperature (in degrees Celsius) was converted to relative units (or points) using the following scale: ≤37.3 С=0 points; 37.4-38.0 С=1 point; 38.1-39.0 С=2 points; ≥39.1 С=3 points. The range of TSS was from &quot;0&quot; to &quot;39&quot;.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Resolution of Acute Respiratory Viral Infection Symptoms (Clinically Diagnosed and/or PCR-confirmed)</measure>
    <time_frame>14 days of observation.</time_frame>
    <description>Acute Respiratory Viral Infection (ARVI) Symptoms resolution criteria: temperature ≤37.3°С + total symptom score (TSS) ≤2. Axillar temperature, 6 flu-like nonspecific symptoms (headache, chills, sweating, weakness, muscle pain, drowsiness) and 6 nasal/throat/chest symptoms (runny nose, nasal congestion, sneezing, hoarseness, sore throat, cough) were registered for TSS according to the 4-point scale for each of them (0 = no symptom; 1 = mild symptom; 2 = moderate symptom; 3 = severe symptom). To calculate TSS absolute axillar temperature (in degrees Celsius) was converted to relative units (or points) using the following scale: ≤37.3 С=0 points; 37.4-38.0 С=1 point; 38.1-39.0 С=2 points; ≥39.1 С=3 points. The range of TSS was from &quot;0&quot; to &quot;39&quot;.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Patients With Resolution of Acute Respiratory Viral Infection (PCR-confirmed)</measure>
    <time_frame>On days 3, 4, 5 and 6 of observation.</time_frame>
    <description>Outcome Measure is based on the Percentage of Patients With Resolution of Acute Respiratory Viral Infection, confirmed by Polymerase chain reaction (PCR), i.e virus detection.&#xD;
Acute Respiratory Viral Infection resolution criteria: temperature ≤37.3°С + total symptom score (TSS) ≤2. Axillar temperature, 6 flu-like nonspecific symptoms (headache, chills, sweating, weakness, muscle pain, drowsiness) and 6 nasal/throat/chest symptoms (runny nose, nasal congestion, sneezing, hoarseness, sore throat, cough) were registered for TSS according to the 4-point scale for each of them (0 = no symptom; 1 = mild symptom; 2 = moderate symptom; 3 = severe symptom). To calculate TSS absolute axillar temperature (in degrees Celsius) was converted to relative units (or points) using the following scale: ≤37.3 С=0 points; 37.4-38.0 С=1 point; 38.1-39.0 С=2 points; ≥39.1 С=3 points. The range of TSS was from &quot;0&quot; to &quot;39&quot;.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Dosing Frequency of Antipyretics.</measure>
    <time_frame>On days 1, 2, 3 of therapy.</time_frame>
    <description>Outcome Measure is based on the rates of antipyretic use per patient during days 1 to 3 of therapy.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Patients Reporting Worsening of Illness</measure>
    <time_frame>From day 4 to day 14 of the observation period.</time_frame>
    <description>Outcome Measure is based on the rates of Complications that require the use of antibiotics or hospitalization.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Occurrence and Characteristics of Adverse Events (AEs)</measure>
    <time_frame>From day 1 to day 7 of the treatment period.</time_frame>
    <description>Severity of AEs, its causal relationship to the study drug, and outcomes.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in Vital Signs: Blood Pressure.</measure>
    <time_frame>On days 1, 5 and 7 of the treatment period.</time_frame>
    <description>Outcome Measure is based on the medical records. Blood Pressure was measured by the physician in every visit (on days 1, 5, and 7).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in Vital Signs: Pulse Rate (Heart Rate).</measure>
    <time_frame>On days 1, 5 and 7 of the treatment period.</time_frame>
    <description>Outcome Measure is based on the medical records. Pulse Rate (Heart Rate) was measured by the physician in every visit (on days 1, 5, and 7).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in Vital Signs: Respiration Rate (Breathing Rate).</measure>
    <time_frame>On days 1, 5 and 7 of the treatment period.</time_frame>
    <description>Outcome Measure is based on the medical records. Respiration Rate (Breathing Rate) was measured by the physician in every visit (on days 1, 5, and 7).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Patients With Clinically Relevant Laboratory Abnormalities</measure>
    <time_frame>From day 1 to day 7 of the treatment period.</time_frame>
    <description>Outcome Measure is based on the Hematology, blood chemistry, and urinalysis parameters, which were beyond the reference values at the end of treatment.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">240</enrollment>
  <condition>Viral Respiratory Infection</condition>
  <arm_group>
    <arm_group_label>MMH-407</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Tablet for oral use. One tablet per intake. On day 1, five tablets are taken in the first 2 hours (one tablet every 30 min), followed by three more tablets regularly spaced during the rest of the day. From day 2 through 5, one tablet is administered three times daily. The drug is administered not during meals (i.e. between the meals or 15-30 minutes before meal). The tablet should be held in mouth until complete dissolution.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>According to the scheme of receiving MMN-407 until the end of the study.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>MMH-407</intervention_name>
    <description>Oral use.</description>
    <arm_group_label>MMH-407</arm_group_label>
    <other_name>Rafamin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Oral use.</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Patients of either gender aged 18-70 years.&#xD;
&#xD;
          2. Diagnosis of ARVI based on medical examination: axillary temperature ≥ 38.0°C at&#xD;
             examination + total general symptoms score ≥4, nasal/throat/chest symptoms score ≥2.&#xD;
&#xD;
          3. The first 24 hours after ARVI onset.&#xD;
&#xD;
          4. Patients giving their consent to use reliable contraception during the study.&#xD;
&#xD;
          5. Signed patient information sheet (informed consent form).&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Clinical symptoms of severe influenza/ARVI requiring hospitalization.&#xD;
&#xD;
          2. Suspected pneumonia, bacterial infection (including otitis media, sinusitis, urinary&#xD;
             tract infection, meningitis, sepsis, etc.) requiring administration of antibiotics&#xD;
             from the first day of illness.&#xD;
&#xD;
          3. Suspected initial manifestations of diseases with symptoms similar to ARVI at onset&#xD;
             (other infectious diseases, flu-like syndrome at the onset of systemic connective&#xD;
             tissue diseases, and other pathology).&#xD;
&#xD;
          4. Patients requiring antiviral medication prohibited within the study.&#xD;
&#xD;
          5. Medical history of primary and secondary immunodeficiency.&#xD;
&#xD;
          6. Medical history/suspicion of oncology of any localization (except for benign&#xD;
             neoplasms).&#xD;
&#xD;
          7. Aggravation or decompensation of chronic diseases affecting a patient's ability to&#xD;
             participate in the clinical trial.&#xD;
&#xD;
          8. Malabsorption syndrome, including congenital or acquired lactase or other&#xD;
             disaccharidase deficiency, galactosemia.&#xD;
&#xD;
          9. Allergy/ hypersensitivity to any component of the study drug.&#xD;
&#xD;
         10. Pregnancy, breast-feeding; childbirth less than 3 months prior to the inclusion in the&#xD;
             trial, unwillingness to use contraceptive methods during the trial.&#xD;
&#xD;
         11. Course administration of the drug products specified in the section &quot;Prohibited&#xD;
             Concomitant Therapy&quot; within two weeks prior to inclusion in the study.&#xD;
&#xD;
         12. Patients who will not fulfill the requirements during the study or follow the order of&#xD;
             administration of the studied drug products, from the Investigator's point of view.&#xD;
&#xD;
         13. Medical history of mental diseases, alcoholism or drug abuse that according to the&#xD;
             investigator's opinion will compromise compliance with the study procedures.&#xD;
&#xD;
         14. Participation in other clinical trials for 3 months prior to enrollment in this study.&#xD;
&#xD;
         15. Patients who are related to any of the on-site research personnel directly involved in&#xD;
             the study or are an immediate relative of the investigator. 'Immediate relative' means&#xD;
             husband, wife, parent, son, daughter, brother, or sister (regardless of whether they&#xD;
             are natural or adopted).&#xD;
&#xD;
         16. Patients who work for OOO &quot;NPF &quot;MATERIA MEDICA HOLDING&quot; (i.e. the company's employees,&#xD;
             temporary contract workers, designated officials responsible for carrying out the&#xD;
             research or any immediate relatives of the aforementioned).&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Altai State Medical University, Department of Faculty Therapy with a course of immunology and allergology</name>
      <address>
        <city>Barnaul</city>
        <zip>656038</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>City Hospital #5</name>
      <address>
        <city>Barnaul</city>
        <zip>656045</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Belgorod State National Research University, Hospital Therapy Department</name>
      <address>
        <city>Belgorod</city>
        <zip>308015</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Road Clinical Hospital at Chelyabinsk station of JSC Russian Railways</name>
      <address>
        <city>Chelyabinsk</city>
        <zip>454000</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>City Clinical Hospital #9 of the Ministry of Health of the Udmurt Republic</name>
      <address>
        <city>Izhevsk</city>
        <zip>426063</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kazan State Medical University, Internal Medicine Department</name>
      <address>
        <city>Kazan</city>
        <zip>420012</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kazan State Medical University, Professorial clinic</name>
      <address>
        <city>Kazan</city>
        <zip>420012</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kuban State Medical University, Infectious Diseases and PhthisiopulmonologyDepartment</name>
      <address>
        <city>Krasnodar</city>
        <zip>350063</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Central Clinical Hospital of the Russian Academy of Sciences</name>
      <address>
        <city>Moscow</city>
        <zip>117593</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Moscow State Medical and Dental University named after A.I. Evdokimov, Pulmonology Laboratory</name>
      <address>
        <city>Moscow</city>
        <zip>127473</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Road Clinical Hospital at the station Nizhny Novgorod of JSC Russian Railways</name>
      <address>
        <city>Nizhniy Novgorod</city>
        <zip>603140</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>City Clinical Hospital #10 of the Kanavinsky District of Nizhny Novgorod</name>
      <address>
        <city>Nizhny Novgorod</city>
        <zip>603011</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Podolsk City Clinical Hospital # 3</name>
      <address>
        <city>Podolsk</city>
        <zip>142105</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>City Emergency Hospital Rostov-on-Don</name>
      <address>
        <city>Rostov-on-Don</city>
        <zip>344068</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ryazan State Medical University named after academician I.P. Pavlov, Department of Outpatient Therapy and Preventive Medicine</name>
      <address>
        <city>Ryazan</city>
        <zip>390026</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vvedensky City Clinical Hospital</name>
      <address>
        <city>Saint Petersburg</city>
        <zip>191180</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>City Polyclinic #25 of the Nevsky District</name>
      <address>
        <city>Saint Petersburg</city>
        <zip>193312</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical Center &quot;Reavita Med SPb&quot;</name>
      <address>
        <city>Saint Petersburg</city>
        <zip>194354</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Road Clinical Hospital of JSC Russian Railways</name>
      <address>
        <city>Saint Petersburg</city>
        <zip>195271</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>City Polyclinic #51</name>
      <address>
        <city>Saint Petersburg</city>
        <zip>196211</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>City Polyclinic #34</name>
      <address>
        <city>Saint Petersburg</city>
        <zip>197198</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>City Polyclinic #43</name>
      <address>
        <city>Saint Petersburg</city>
        <zip>198207</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Samara City Hospital #4</name>
      <address>
        <city>Samara</city>
        <zip>443056</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Scientific Medical Center for General Therapy and Pharmacology</name>
      <address>
        <city>Stavropol</city>
        <zip>355000</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bashkir State Medical University, Internal Medicine Department</name>
      <address>
        <city>Ufa</city>
        <zip>450008</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Volgograd State Medical University</name>
      <address>
        <city>Volgograd</city>
        <zip>400131</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Russian Federation</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>December 13, 2019</study_first_submitted>
  <study_first_submitted_qc>January 27, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">January 28, 2020</study_first_posted>
  <results_first_submitted>May 24, 2021</results_first_submitted>
  <results_first_submitted_qc>September 8, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">October 6, 2021</results_first_posted>
  <last_update_submitted>October 5, 2021</last_update_submitted>
  <last_update_submitted_qc>October 5, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 3, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infections</mesh_term>
    <mesh_term>Communicable Diseases</mesh_term>
    <mesh_term>Respiratory Tract Infections</mesh_term>
    <mesh_term>Virus Diseases</mesh_term>
  </condition_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>July 1, 2019</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/84/NCT04244084/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>MMH-407</title>
          <description>Oral administration. Single dose: 1 tablet. First 24 hours of therapy: 1 tablet every 30 minutes for the first 2 hours, followed by 3 more tablets taken at regular intervals during the rest of the day.&#xD;
Days 2 to 5: 1 tablet 3 times daily. The product must not be taken with food, but in between meals or 15-30 minutes before meal; each tablet must be held in the mouth to let it dissolve completely before it can be swallowed.&#xD;
MMH-407: Oral administration.</description>
        </group>
        <group group_id="P2">
          <title>Placebo</title>
          <description>According to the scheme of receiving MMN-407 until the end of the study.&#xD;
Placebo: Oral administration.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="118"/>
                <participants group_id="P2" count="122"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="118"/>
                <participants group_id="P2" count="122"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>MMH-407</title>
          <description>Oral administration. Single dose: 1 tablet. First 24 hours of therapy: 1 tablet every 30 minutes for the first 2 hours, followed by 3 more tablets taken at regular intervals during the rest of the day.&#xD;
Days 2 to 5: 1 tablet 3 times daily. The product must not be taken with food, but in between meals or 15-30 minutes before meal; each tablet must be held in the mouth to let it dissolve completely before it can be swallowed.&#xD;
MMH-407: Oral administration.</description>
        </group>
        <group group_id="B2">
          <title>Placebo</title>
          <description>According to the scheme of receiving MMN-407 until the end of the study.&#xD;
Placebo: Oral administration.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="118"/>
            <count group_id="B2" value="122"/>
            <count group_id="B3" value="240"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="118"/>
                    <count group_id="B2" value="122"/>
                    <count group_id="B3" value="240"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="38.5" spread="12.6"/>
                    <measurement group_id="B2" value="38.5" spread="11.6"/>
                    <measurement group_id="B3" value="38.5" spread="12.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="118"/>
                    <count group_id="B2" value="122"/>
                    <count group_id="B3" value="240"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="79"/>
                    <measurement group_id="B2" value="68"/>
                    <measurement group_id="B3" value="147"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="39"/>
                    <measurement group_id="B2" value="54"/>
                    <measurement group_id="B3" value="93"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race and Ethnicity Not Collected</title>
          <population>Race and Ethnicity were not collected from any participant.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="0"/>
                    <count group_id="B2" value="0"/>
                    <count group_id="B3" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Russia</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="118"/>
                    <count group_id="B2" value="122"/>
                    <count group_id="B3" value="240"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="118"/>
                    <measurement group_id="B2" value="122"/>
                    <measurement group_id="B3" value="240"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Time to Resolution of Acute Respiratory Viral Infection (ARVI) Symptoms</title>
        <description>Outcome Measure is evaluated on the basis of the &quot;ARVI severity scale&quot; to calculate total symptom score (TSS) in patients with confirmed virus by Polymerase chain reaction (PCR).&#xD;
ARVI's resolution criteria: temperature ≤37.3°С + TSS ≤2. Axillar temperature, 6 flu-like nonspecific symptoms (headache, chills, sweating, weakness, muscle pain, drowsiness), and 6 nasal/throat/chest symptoms (runny nose, nasal congestion, sneezing, hoarseness, sore throat, cough) were registered for TSS according to the 4-point scale for each of them (0 = no symptom; 1 = mild symptom; 2 = moderate symptom; 3 = severe symptom). To calculate TSS absolute axillar temperature (in degrees Celsius) was converted to relative units (or points) using the following scale: ≤37.3 С=0 points; 37.4-38.0 С=1 point; 38.1-39.0 С=2 points; ≥39.1 С=3 points. The range of TSS was from &quot;0&quot; to &quot;39&quot;.</description>
        <time_frame>14 days of observation.</time_frame>
        <group_list>
          <group group_id="O1">
            <title>MMH-407</title>
            <description>Oral administration. Single dose: 1 tablet. First 24 hours of therapy: 1 tablet every 30 minutes for the first 2 hours, followed by 3 more tablets taken at regular intervals during the rest of the day.&#xD;
Days 2 to 5: 1 tablet 3 times daily. The product must not be taken with food, but in between meals or 15-30 minutes before meal; each tablet must be held in the mouth to let it dissolve completely before it can be swallowed.&#xD;
MMH-407: Oral administration.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>According to the scheme of receiving MMN-407 until the end of the study.&#xD;
Placebo: Oral administration.</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Resolution of Acute Respiratory Viral Infection (ARVI) Symptoms</title>
          <description>Outcome Measure is evaluated on the basis of the &quot;ARVI severity scale&quot; to calculate total symptom score (TSS) in patients with confirmed virus by Polymerase chain reaction (PCR).&#xD;
ARVI's resolution criteria: temperature ≤37.3°С + TSS ≤2. Axillar temperature, 6 flu-like nonspecific symptoms (headache, chills, sweating, weakness, muscle pain, drowsiness), and 6 nasal/throat/chest symptoms (runny nose, nasal congestion, sneezing, hoarseness, sore throat, cough) were registered for TSS according to the 4-point scale for each of them (0 = no symptom; 1 = mild symptom; 2 = moderate symptom; 3 = severe symptom). To calculate TSS absolute axillar temperature (in degrees Celsius) was converted to relative units (or points) using the following scale: ≤37.3 С=0 points; 37.4-38.0 С=1 point; 38.1-39.0 С=2 points; ≥39.1 С=3 points. The range of TSS was from &quot;0&quot; to &quot;39&quot;.</description>
          <units>days</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="78"/>
                <count group_id="O2" value="73"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.1" spread="1.9"/>
                    <measurement group_id="O2" value="5.0" spread="2.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Mean differences (MMH-407 vs. Placebo) were compared</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0155</p_value>
            <method>ANCOVA</method>
            <method_desc>Site used as covariate</method_desc>
            <param_type>Median Difference (Final Values)</param_type>
            <param_value>-0.89</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.61</ci_lower_limit>
            <ci_upper_limit>-0.17</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Severity of ARVI (Clinically Diagnosed and/or PCR-confirmed)</title>
        <description>Outcome Measure is based on the area under the curve (AUC) for TSS. AUC was calculated between 6 points (by TSS for every 6 days of the treatment and observation). The minimum value for the AUC was &quot;0&quot; and the maximum value was &quot;234&quot; units (day*score). Higher TSS and AUC scores meant worse results.</description>
        <time_frame>On days 1- 6 of the observation.</time_frame>
        <group_list>
          <group group_id="O1">
            <title>MMH-407</title>
            <description>Oral administration. Single dose: 1 tablet. First 24 hours of therapy: 1 tablet every 30 minutes for the first 2 hours, followed by 3 more tablets taken at regular intervals during the rest of the day.&#xD;
Days 2 to 5: 1 tablet 3 times daily. The product must not be taken with food, but in between meals or 15-30 minutes before meal; each tablet must be held in the mouth to let it dissolve completely before it can be swallowed.&#xD;
MMH-407: Oral administration.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>According to the scheme of receiving MMN-407 until the end of the study.&#xD;
Placebo: Oral administration.</description>
          </group>
        </group_list>
        <measure>
          <title>Severity of ARVI (Clinically Diagnosed and/or PCR-confirmed)</title>
          <description>Outcome Measure is based on the area under the curve (AUC) for TSS. AUC was calculated between 6 points (by TSS for every 6 days of the treatment and observation). The minimum value for the AUC was &quot;0&quot; and the maximum value was &quot;234&quot; units (day*score). Higher TSS and AUC scores meant worse results.</description>
          <units>day*score</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="118"/>
                <count group_id="O2" value="122"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="48.5" spread="21.7"/>
                    <measurement group_id="O2" value="52.6" spread="24.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.1839</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Patients With Resolution of ARVI Symptoms (Clinically Diagnosed and/or PCR-confirmed)</title>
        <description>ARVI's resolution criteria: temperature ≤37.3°С + total symptom score (TSS) ≤2. Axillar temperature, 6 flu-like nonspecific symptoms (headache, chills, sweating, weakness, muscle pain, drowsiness) and 6 nasal/throat/chest symptoms (runny nose, nasal congestion, sneezing, hoarseness, sore throat, cough) were registered for TSS according to the 4-point scale for each of them (0 = no symptom; 1 = mild symptom; 2 = moderate symptom; 3 = severe symptom). To calculate TSS absolute axillar temperature (in degrees Celsius) was converted to relative units (or points) using the following scale: ≤37.3 С=0 points; 37.4-38.0 С=1 point; 38.1-39.0 С=2 points; ≥39.1 С=3 points. The range of TSS was from &quot;0&quot; to &quot;39&quot;.</description>
        <time_frame>On days 3, 4, 5 and 6 of observation.</time_frame>
        <group_list>
          <group group_id="O1">
            <title>MMH-407</title>
            <description>Oral administration. Single dose: 1 tablet. First 24 hours of therapy: 1 tablet every 30 minutes for the first 2 hours, followed by 3 more tablets taken at regular intervals during the rest of the day.&#xD;
Days 2 to 5: 1 tablet 3 times daily. The product must not be taken with food, but in between meals or 15-30 minutes before meal; each tablet must be held in the mouth to let it dissolve completely before it can be swallowed.&#xD;
MMH-407: Oral administration.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>According to the scheme of receiving MMN-407 until the end of the study.&#xD;
Placebo: Oral administration.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Patients With Resolution of ARVI Symptoms (Clinically Diagnosed and/or PCR-confirmed)</title>
          <description>ARVI's resolution criteria: temperature ≤37.3°С + total symptom score (TSS) ≤2. Axillar temperature, 6 flu-like nonspecific symptoms (headache, chills, sweating, weakness, muscle pain, drowsiness) and 6 nasal/throat/chest symptoms (runny nose, nasal congestion, sneezing, hoarseness, sore throat, cough) were registered for TSS according to the 4-point scale for each of them (0 = no symptom; 1 = mild symptom; 2 = moderate symptom; 3 = severe symptom). To calculate TSS absolute axillar temperature (in degrees Celsius) was converted to relative units (or points) using the following scale: ≤37.3 С=0 points; 37.4-38.0 С=1 point; 38.1-39.0 С=2 points; ≥39.1 С=3 points. The range of TSS was from &quot;0&quot; to &quot;39&quot;.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="118"/>
                <count group_id="O2" value="122"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15"/>
                    <measurement group_id="O2" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="44"/>
                    <measurement group_id="O2" value="38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 5</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="74"/>
                    <measurement group_id="O2" value="70"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 6</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="86"/>
                    <measurement group_id="O2" value="85"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0640</p_value>
            <p_value_desc>Day used as independent strata.</p_value_desc>
            <method>Cochran-Mantel-Haenszel</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to Resolution of Acute Respiratory Viral Infection Symptoms (Clinically Diagnosed and/or PCR-confirmed)</title>
        <description>Acute Respiratory Viral Infection (ARVI) Symptoms resolution criteria: temperature ≤37.3°С + total symptom score (TSS) ≤2. Axillar temperature, 6 flu-like nonspecific symptoms (headache, chills, sweating, weakness, muscle pain, drowsiness) and 6 nasal/throat/chest symptoms (runny nose, nasal congestion, sneezing, hoarseness, sore throat, cough) were registered for TSS according to the 4-point scale for each of them (0 = no symptom; 1 = mild symptom; 2 = moderate symptom; 3 = severe symptom). To calculate TSS absolute axillar temperature (in degrees Celsius) was converted to relative units (or points) using the following scale: ≤37.3 С=0 points; 37.4-38.0 С=1 point; 38.1-39.0 С=2 points; ≥39.1 С=3 points. The range of TSS was from &quot;0&quot; to &quot;39&quot;.</description>
        <time_frame>14 days of observation.</time_frame>
        <group_list>
          <group group_id="O1">
            <title>MMH-407</title>
            <description>Oral administration. Single dose: 1 tablet. First 24 hours of therapy: 1 tablet every 30 minutes for the first 2 hours, followed by 3 more tablets taken at regular intervals during the rest of the day.&#xD;
Days 2 to 5: 1 tablet 3 times daily. The product must not be taken with food, but in between meals or 15-30 minutes before meal; each tablet must be held in the mouth to let it dissolve completely before it can be swallowed.&#xD;
MMH-407: Oral administration.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>According to the scheme of receiving MMN-407 until the end of the study.&#xD;
Placebo: Oral administration.</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Resolution of Acute Respiratory Viral Infection Symptoms (Clinically Diagnosed and/or PCR-confirmed)</title>
          <description>Acute Respiratory Viral Infection (ARVI) Symptoms resolution criteria: temperature ≤37.3°С + total symptom score (TSS) ≤2. Axillar temperature, 6 flu-like nonspecific symptoms (headache, chills, sweating, weakness, muscle pain, drowsiness) and 6 nasal/throat/chest symptoms (runny nose, nasal congestion, sneezing, hoarseness, sore throat, cough) were registered for TSS according to the 4-point scale for each of them (0 = no symptom; 1 = mild symptom; 2 = moderate symptom; 3 = severe symptom). To calculate TSS absolute axillar temperature (in degrees Celsius) was converted to relative units (or points) using the following scale: ≤37.3 С=0 points; 37.4-38.0 С=1 point; 38.1-39.0 С=2 points; ≥39.1 С=3 points. The range of TSS was from &quot;0&quot; to &quot;39&quot;.</description>
          <units>days</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="118"/>
                <count group_id="O2" value="122"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.4" spread="2.2"/>
                    <measurement group_id="O2" value="4.8" spread="2.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.1927</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Patients With Resolution of Acute Respiratory Viral Infection (PCR-confirmed)</title>
        <description>Outcome Measure is based on the Percentage of Patients With Resolution of Acute Respiratory Viral Infection, confirmed by Polymerase chain reaction (PCR), i.e virus detection.&#xD;
Acute Respiratory Viral Infection resolution criteria: temperature ≤37.3°С + total symptom score (TSS) ≤2. Axillar temperature, 6 flu-like nonspecific symptoms (headache, chills, sweating, weakness, muscle pain, drowsiness) and 6 nasal/throat/chest symptoms (runny nose, nasal congestion, sneezing, hoarseness, sore throat, cough) were registered for TSS according to the 4-point scale for each of them (0 = no symptom; 1 = mild symptom; 2 = moderate symptom; 3 = severe symptom). To calculate TSS absolute axillar temperature (in degrees Celsius) was converted to relative units (or points) using the following scale: ≤37.3 С=0 points; 37.4-38.0 С=1 point; 38.1-39.0 С=2 points; ≥39.1 С=3 points. The range of TSS was from &quot;0&quot; to &quot;39&quot;.</description>
        <time_frame>On days 3, 4, 5 and 6 of observation.</time_frame>
        <group_list>
          <group group_id="O1">
            <title>MMH-407</title>
            <description>Oral administration. Single dose: 1 tablet. First 24 hours of therapy: 1 tablet every 30 minutes for the first 2 hours, followed by 3 more tablets taken at regular intervals during the rest of the day.&#xD;
Days 2 to 5: 1 tablet 3 times daily. The product must not be taken with food, but in between meals or 15-30 minutes before meal; each tablet must be held in the mouth to let it dissolve completely before it can be swallowed.&#xD;
MMH-407: Oral administration.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>According to the scheme of receiving MMN-407 until the end of the study.&#xD;
Placebo: Oral administration.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Patients With Resolution of Acute Respiratory Viral Infection (PCR-confirmed)</title>
          <description>Outcome Measure is based on the Percentage of Patients With Resolution of Acute Respiratory Viral Infection, confirmed by Polymerase chain reaction (PCR), i.e virus detection.&#xD;
Acute Respiratory Viral Infection resolution criteria: temperature ≤37.3°С + total symptom score (TSS) ≤2. Axillar temperature, 6 flu-like nonspecific symptoms (headache, chills, sweating, weakness, muscle pain, drowsiness) and 6 nasal/throat/chest symptoms (runny nose, nasal congestion, sneezing, hoarseness, sore throat, cough) were registered for TSS according to the 4-point scale for each of them (0 = no symptom; 1 = mild symptom; 2 = moderate symptom; 3 = severe symptom). To calculate TSS absolute axillar temperature (in degrees Celsius) was converted to relative units (or points) using the following scale: ≤37.3 С=0 points; 37.4-38.0 С=1 point; 38.1-39.0 С=2 points; ≥39.1 С=3 points. The range of TSS was from &quot;0&quot; to &quot;39&quot;.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="78"/>
                <count group_id="O2" value="73"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12"/>
                    <measurement group_id="O2" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28"/>
                    <measurement group_id="O2" value="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 5</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="54"/>
                    <measurement group_id="O2" value="38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 6</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="60"/>
                    <measurement group_id="O2" value="48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0014</p_value>
            <p_value_desc>Day used as independent strata.</p_value_desc>
            <method>Cochran-Mantel-Haenszel</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Dosing Frequency of Antipyretics.</title>
        <description>Outcome Measure is based on the rates of antipyretic use per patient during days 1 to 3 of therapy.</description>
        <time_frame>On days 1, 2, 3 of therapy.</time_frame>
        <group_list>
          <group group_id="O1">
            <title>MMH-407</title>
            <description>Oral administration. Single dose: 1 tablet. First 24 hours of therapy: 1 tablet every 30 minutes for the first 2 hours, followed by 3 more tablets taken at regular intervals during the rest of the day.&#xD;
Days 2 to 5: 1 tablet 3 times daily. The product must not be taken with food, but in between meals or 15-30 minutes before meal; each tablet must be held in the mouth to let it dissolve completely before it can be swallowed.&#xD;
MMH-407: Oral administration.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>According to the scheme of receiving MMN-407 until the end of the study.&#xD;
Placebo: Oral administration.</description>
          </group>
        </group_list>
        <measure>
          <title>Dosing Frequency of Antipyretics.</title>
          <description>Outcome Measure is based on the rates of antipyretic use per patient during days 1 to 3 of therapy.</description>
          <units>number of doses</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="118"/>
                <count group_id="O2" value="122"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.30" spread="0.68"/>
                    <measurement group_id="O2" value="0.38" spread="0.67"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.19" spread="0.48"/>
                    <measurement group_id="O2" value="0.24" spread="0.53"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.03" spread="0.22"/>
                    <measurement group_id="O2" value="0.04" spread="0.20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>This analysis applies to &quot;Day 1&quot; row.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.2009</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>This analysis applies to &quot;Day 2&quot; row.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.4717</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>This analysis applies to &quot;Day 3&quot; row.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.5144</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Patients Reporting Worsening of Illness</title>
        <description>Outcome Measure is based on the rates of Complications that require the use of antibiotics or hospitalization.</description>
        <time_frame>From day 4 to day 14 of the observation period.</time_frame>
        <group_list>
          <group group_id="O1">
            <title>MMH-407</title>
            <description>Oral administration. Single dose: 1 tablet. First 24 hours of therapy: 1 tablet every 30 minutes for the first 2 hours, followed by 3 more tablets taken at regular intervals during the rest of the day.&#xD;
Days 2 to 5: 1 tablet 3 times daily. The product must not be taken with food, but in between meals or 15-30 minutes before meal; each tablet must be held in the mouth to let it dissolve completely before it can be swallowed.&#xD;
MMH-407: Oral administration.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>According to the scheme of receiving MMN-407 until the end of the study.&#xD;
Placebo: Oral administration.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Patients Reporting Worsening of Illness</title>
          <description>Outcome Measure is based on the rates of Complications that require the use of antibiotics or hospitalization.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="118"/>
                <count group_id="O2" value="122"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.62</p_value>
            <method>Fisher Exact</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Occurrence and Characteristics of Adverse Events (AEs)</title>
        <description>Severity of AEs, its causal relationship to the study drug, and outcomes.</description>
        <time_frame>From day 1 to day 7 of the treatment period.</time_frame>
        <group_list>
          <group group_id="O1">
            <title>MMH-407</title>
            <description>Oral administration. Single dose: 1 tablet. First 24 hours of therapy: 1 tablet every 30 minutes for the first 2 hours, followed by 3 more tablets taken at regular intervals during the rest of the day.&#xD;
Days 2 to 5: 1 tablet 3 times daily. The product must not be taken with food, but in between meals or 15-30 minutes before meal; each tablet must be held in the mouth to let it dissolve completely before it can be swallowed.&#xD;
MMH-407: Oral administration.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>According to the scheme of receiving MMN-407 until the end of the study.&#xD;
Placebo: Oral administration.</description>
          </group>
        </group_list>
        <measure>
          <title>Occurrence and Characteristics of Adverse Events (AEs)</title>
          <description>Severity of AEs, its causal relationship to the study drug, and outcomes.</description>
          <units>Number of events</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="118"/>
                <count group_id="O2" value="122"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Number of AE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                    <measurement group_id="O2" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mild severity</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                    <measurement group_id="O2" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>No relationship with the study drug</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                    <measurement group_id="O2" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Probable relationship to study drug</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Changes in Vital Signs: Blood Pressure.</title>
        <description>Outcome Measure is based on the medical records. Blood Pressure was measured by the physician in every visit (on days 1, 5, and 7).</description>
        <time_frame>On days 1, 5 and 7 of the treatment period.</time_frame>
        <group_list>
          <group group_id="O1">
            <title>MMH-407</title>
            <description>Oral administration. Single dose: 1 tablet. First 24 hours of therapy: 1 tablet every 30 minutes for the first 2 hours, followed by 3 more tablets taken at regular intervals during the rest of the day.&#xD;
Days 2 to 5: 1 tablet 3 times daily. The product must not be taken with food, but in between meals or 15-30 minutes before meal; each tablet must be held in the mouth to let it dissolve completely before it can be swallowed.&#xD;
MMH-407: Oral administration.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>According to the scheme of receiving MMN-407 until the end of the study.&#xD;
Placebo: Oral administration.</description>
          </group>
        </group_list>
        <measure>
          <title>Changes in Vital Signs: Blood Pressure.</title>
          <description>Outcome Measure is based on the medical records. Blood Pressure was measured by the physician in every visit (on days 1, 5, and 7).</description>
          <units>mmHg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="118"/>
                <count group_id="O2" value="122"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Systolic blood pressure/Visit 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="121.0" spread="10.0"/>
                    <measurement group_id="O2" value="121.0" spread="10.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Systolic blood pressure/Visit 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="120.0" spread="8.5"/>
                    <measurement group_id="O2" value="120.0" spread="8.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Systolic blood pressure/Visit 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="120.0" spread="8.2"/>
                    <measurement group_id="O2" value="119.0" spread="9.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Diastolic blood pressure/Visit 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="75.0" spread="7.5"/>
                    <measurement group_id="O2" value="75.1" spread="7.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Diastolic blood pressure/Visit 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="74.9" spread="6.3"/>
                    <measurement group_id="O2" value="74.8" spread="6.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Diastolic blood pressure/Visit 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="74.6" spread="6.6"/>
                    <measurement group_id="O2" value="74.8" spread="7.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>This analysis applies to &quot;Systolic blood pressure/Visit 1&quot; row.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.5981</p_value>
            <method>Kruskal-Wallis</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>This analysis applies to &quot;Systolic blood pressure/Visit 2&quot; row.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.4913</p_value>
            <method>Kruskal-Wallis</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>This analysis applies to &quot;Systolic blood pressure/Visit 3&quot; row.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.6441</p_value>
            <method>Kruskal-Wallis</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>This analysis applies to &quot;Diastolic blood pressure/Visit 1&quot; row.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.8186</p_value>
            <method>Kruskal-Wallis</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>This analysis applies to &quot;Diastolic blood pressure/Visit 2&quot; row.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.8931</p_value>
            <method>Kruskal-Wallis</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>This analysis applies to &quot;Diastolic blood pressure/Visit 3&quot; row.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.5887</p_value>
            <method>Kruskal-Wallis</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Changes in Vital Signs: Pulse Rate (Heart Rate).</title>
        <description>Outcome Measure is based on the medical records. Pulse Rate (Heart Rate) was measured by the physician in every visit (on days 1, 5, and 7).</description>
        <time_frame>On days 1, 5 and 7 of the treatment period.</time_frame>
        <group_list>
          <group group_id="O1">
            <title>MMH-407</title>
            <description>Oral administration. Single dose: 1 tablet. First 24 hours of therapy: 1 tablet every 30 minutes for the first 2 hours, followed by 3 more tablets taken at regular intervals during the rest of the day.&#xD;
Days 2 to 5: 1 tablet 3 times daily. The product must not be taken with food, but in between meals or 15-30 minutes before meal; each tablet must be held in the mouth to let it dissolve completely before it can be swallowed.&#xD;
MMH-407: Oral administration.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>According to the scheme of receiving MMN-407 until the end of the study.&#xD;
Placebo: Oral administration.</description>
          </group>
        </group_list>
        <measure>
          <title>Changes in Vital Signs: Pulse Rate (Heart Rate).</title>
          <description>Outcome Measure is based on the medical records. Pulse Rate (Heart Rate) was measured by the physician in every visit (on days 1, 5, and 7).</description>
          <units>bpm</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="118"/>
                <count group_id="O2" value="122"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Heart rate/Visit 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="86.9" spread="12.9"/>
                    <measurement group_id="O2" value="88.0" spread="13.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Heart rate/Visit 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="73.5" spread="7.4"/>
                    <measurement group_id="O2" value="74.4" spread="9.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Heart rate/Visit 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="71.1" spread="5.8"/>
                    <measurement group_id="O2" value="71.7" spread="7.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>This analysis applies to &quot;Heart rate/Visit 1&quot; row.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.4426</p_value>
            <method>Kruskal-Wallis</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>This analysis applies to &quot;Heart rate/Visit 2&quot; row.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.5998</p_value>
            <method>Kruskal-Wallis</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>This analysis applies to &quot;Heart rate/Visit 3&quot; row.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.9710</p_value>
            <method>Kruskal-Wallis</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Changes in Vital Signs: Respiration Rate (Breathing Rate).</title>
        <description>Outcome Measure is based on the medical records. Respiration Rate (Breathing Rate) was measured by the physician in every visit (on days 1, 5, and 7).</description>
        <time_frame>On days 1, 5 and 7 of the treatment period.</time_frame>
        <group_list>
          <group group_id="O1">
            <title>MMH-407</title>
            <description>Oral administration. Single dose: 1 tablet. First 24 hours of therapy: 1 tablet every 30 minutes for the first 2 hours, followed by 3 more tablets taken at regular intervals during the rest of the day.&#xD;
Days 2 to 5: 1 tablet 3 times daily. The product must not be taken with food, but in between meals or 15-30 minutes before meal; each tablet must be held in the mouth to let it dissolve completely before it can be swallowed.&#xD;
MMH-407: Oral administration.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>According to the scheme of receiving MMN-407 until the end of the study.&#xD;
Placebo: Oral administration.</description>
          </group>
        </group_list>
        <measure>
          <title>Changes in Vital Signs: Respiration Rate (Breathing Rate).</title>
          <description>Outcome Measure is based on the medical records. Respiration Rate (Breathing Rate) was measured by the physician in every visit (on days 1, 5, and 7).</description>
          <units>breaths/min</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="118"/>
                <count group_id="O2" value="122"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Breathing rate/Visit 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17.4" spread="1.6"/>
                    <measurement group_id="O2" value="17.5" spread="1.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Breathing rate/Visit 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16.6" spread="1.4"/>
                    <measurement group_id="O2" value="16.7" spread="1.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Breathing rate/Visit 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16.4" spread="1.3"/>
                    <measurement group_id="O2" value="16.4" spread="1.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>This analysis applies to &quot;Breathing rate/Visit 1&quot; row.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.6197</p_value>
            <method>Kruskal-Wallis</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>This analysis applies to &quot;Breathing rate/Visit 2&quot; row.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.7042</p_value>
            <method>Kruskal-Wallis</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>This analysis applies to &quot;Breathing rate/Visit 3&quot; row.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.7693</p_value>
            <method>Kruskal-Wallis</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Patients With Clinically Relevant Laboratory Abnormalities</title>
        <description>Outcome Measure is based on the Hematology, blood chemistry, and urinalysis parameters, which were beyond the reference values at the end of treatment.</description>
        <time_frame>From day 1 to day 7 of the treatment period.</time_frame>
        <group_list>
          <group group_id="O1">
            <title>MMH-407</title>
            <description>Oral administration. Single dose: 1 tablet. First 24 hours of therapy: 1 tablet every 30 minutes for the first 2 hours, followed by 3 more tablets taken at regular intervals during the rest of the day.&#xD;
Days 2 to 5: 1 tablet 3 times daily. The product must not be taken with food, but in between meals or 15-30 minutes before meal; each tablet must be held in the mouth to let it dissolve completely before it can be swallowed.&#xD;
MMH-407: Oral administration.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>According to the scheme of receiving MMN-407 until the end of the study.&#xD;
Placebo: Oral administration.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Patients With Clinically Relevant Laboratory Abnormalities</title>
          <description>Outcome Measure is based on the Hematology, blood chemistry, and urinalysis parameters, which were beyond the reference values at the end of treatment.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="118"/>
                <count group_id="O2" value="122"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>1.000</p_value>
            <method>Fisher Exact</method>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>During 6 days (start after taking the first dose of the study drug, during the entire period of the study therapy - 5 days and within 24 hours after the last dose of the study drug).</time_frame>
      <group_list>
        <group group_id="E1">
          <title>MMH-407</title>
          <description>Oral administration. Single dose: 1 tablet. First 24 hours of therapy: 1 tablet every 30 minutes for the first 2 hours, followed by 3 more tablets taken at regular intervals during the rest of the day.&#xD;
Days 2 to 5: 1 tablet 3 times daily. The product must not be taken with food, but in between meals or 15-30 minutes before meal; each tablet must be held in the mouth to let it dissolve completely before it can be swallowed.&#xD;
MMH-407: Oral administration.</description>
        </group>
        <group group_id="E2">
          <title>Placebo</title>
          <description>According to the scheme of receiving MMN-407 until the end of the study.&#xD;
Placebo: Oral administration.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="118"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="122"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="118"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="122"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Community-acquired pneumonia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="118"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="122"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>MedDRA</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="118"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="118"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Epigastric pain</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="118"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="118"/>
              </event>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="118"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="118"/>
              </event>
              <event>
                <sub_title>Dry mouth</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="118"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="118"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="118"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="118"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Edema of the lips and face</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="118"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="118"/>
              </event>
              <event>
                <sub_title>Worsening of the disease</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="118"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="118"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Sinusitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="118"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="118"/>
              </event>
              <event>
                <sub_title>Purulent bronchitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="118"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="118"/>
              </event>
              <event>
                <sub_title>Acute nasopharyngitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="118"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="118"/>
              </event>
              <event>
                <sub_title>Acute tubootitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="118"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="118"/>
              </event>
              <event>
                <sub_title>Herpes simplex</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="118"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="118"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Increase in the percentage of basophils</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="118"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="118"/>
              </event>
              <event>
                <sub_title>Increase in the percentage of eosinophils</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="118"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="118"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Intercostal neuralgia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="118"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="118"/>
              </event>
              <event>
                <sub_title>Migraine</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="118"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="118"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Exacerbation of bronchial asthma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="118"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="118"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There IS an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Mikhail Putilovskiy, MD, PhD, Clinical and Medical Department Director</name_or_title>
      <organization>MATERIA MEDICA HOLDING</organization>
      <phone>+74952761571 ext 302</phone>
      <email>PutilovskiyMA@materiamedica.ru</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

